AmoyDx and Premia will provide large-scale cancer patient screening in Asia to support Loxo-292 RET inhibitor clinical development.
The kit is approved for the qualitative detection of BRCA1 and BRCA2 mutations in patients with different cancer types including breast cancer.
AmoyDx's kit is designed to detect hotspot mutations/fusions in nine genes to help guide treatment decisions for non-small cell lung cancer patients.
The companion diagnostic for Pfizer's Xalkori identifies 14 ROS1 gene fusions by analyzing tumor messenger RNA from human tumor tissue or body fluids.
AmoyDx's molecular diagnostics tests, powered by its ADx-ARMS and Super-ARMS technologies, will be made available in Hong Kong and Macau.
The real-time PCR-based test is designed to identify EGFR mutations in circulating tumor DNA in plasma samples.
Amoy will supply its CD95 IHC and CpG2 qPCR kits to develop a companion diagnostic for Canbridge's lead product targeting recurrent glioblastoma multiforme.
The firm's ROS1 gene fusion kit was approved as a companion diagnostic for Pfizer's Xalkori.
The test, which will be based on AmoyDx's proprietary real-time PCR technology, will identify cancer-associated mutations in the RAS gene family.
AmoyDx will develop and commercialize a series of oncology tests that use Illumina NGS technology, including the firm's TruSight Tumor 15 panel.
The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.
US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.
Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.
In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.